Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. Its transforming growth factor beta (TGFß) superfamily biology, its novel understanding of the molecular mechanisms of growth factor activation enabled us to develop a proprietary platform for development of monoclonal antibodies that locally and selectively target the precursor. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is developing a pipeline of product candidates to deliver novel therapies to treat a range of serious diseases, including neuromuscular disorders, cardiometabolic disorders, cancer, fibrosis, and iron-restricted anemia. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.

Period	Debt/Equity
2018-12-31	0.70
2019-12-31	0.74
2020-12-31	0.49
2021-12-31	0.77
2022-12-31	0.38
2023-12-31	0.38
2024-12-31	0.29

	A	B	C	D
1	Symbol	Price	Change	Volume
2	SRRK	$49.19	+0.00%	1.32M
3
4
5

Scholar Rock Holding Corporation (SRRK) Debt to Equity Ratio

Debt to Equity Ratio Data

Get Scholar Rock Holding Corporation Data in Excel

More SRRK Financial Data